**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 57361

**Manuscript Type:** MINIREVIEWS

**Overlooked risk for needle tract seeding following endoscopic ultrasound-guided minimally invasive tissue acquisition**

Gao RY *et al*. Needle tract seeding following EUS-FNA/FNB

Ruo-Yu Gao, Ben-Hua Wu, Xin-Ying Shen, Tie-Li Peng, De-Feng Li, Cheng Wei, Zhi-Chao Yu, Ming-Han Luo, Feng Xiong, Li-Sheng Wang, Jun Yao

**Ruo-Yu Gao, Ben-Hua Wu, De-Feng Li, Cheng Wei, Zhi-Chao Yu, Ming-Han Luo, Feng Xiong, Li-Sheng Wang, Jun Yao,** Department of Gastroenterology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China

**Xin-Ying Shen,** Department of Interventional Medicine, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China

**Tie-Li Peng,** Department of Gastroenterology, Institute of Digestive Disease of Guangzhou Medical University, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan 511500, Guangdong Province, China

**Author contributions:** Gao RY prepared the tables and drafted the manuscript; Wu BH, Shen XY, Peng TL, Li DF, Wei C, Yu ZC, Luo MH, and Xiong F reviewed the manuscript for its intellectual content; Wang LS and Yao J were responsible for revising the manuscript; all authors have read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 81800489.

**Corresponding author: Jun Yao, PhD, Doctor,** Department of Gastroenterology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, No. 1017 East Gate Road, Shenzhen 518020, Guangdong Province, China. yj\_1108@126.com

**Received:** June 8, 2020

**Revised:** August 5, 2020

**Accepted:** September 17, 2020

**Published online:**

**Abstract**

Endoscopic ultrasound-guided minimally invasive tissue acquisition can be performed by two approaches as follows: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB). These have been evolved into leading approaches and widely used for the histological diagnosis of tumors in the gastrointestinal tract and adjacent organs. However, the role of EUS-FNA and EUS-FNB in disease diagnosis and evaluation remains controversial. Although the incidence of surgery-associated complications remains low, the consequences of needle tract seeding can be serious or even life-threatening. Recently, increasing case reports of needle tract seeding are emerging, especially caused by EUS-FNA. This complication needs serious consideration. In the present work, we integrated these case reports and the related literature, and summarized the relevant cases and technical characteristics of needle tract seeding caused by EUS-FNA and EUS-FNB. Collectively, our findings provided valuable insights into the prevention and reduction of such serious complication.

**Key Words:** Endoscopic ultrasound-guided fine-needle aspiration; Endoscopic ultrasound-guided fine-needle biopsy; Needle tract seeding; Gastrointestinal tract; Computed tomography

Gao RY, Wu BH, Shen XY, Peng TL, Li DF, Wei C, Yu ZC, Luo MH, Xiong F, Wang LS, Yao J. Overlooked risk for needle tract seeding following endoscopic ultrasound -guided minimally invasive tissue acquisition. *World J Gastroenterol* 2020; In press

**Core Tip:** This paper integrates for the first time the case reports and related literature of needle tract seeding caused by endoscopic ultrasound-guided fine-needle aspiration or biopsy, and summarizes in detail the case characteristics of needle tract seeding, including the time interval, tumor location, effective detection methods, the relationship between treatment and prognosis, and the risk factors that may lead to needle tract seeding. Our findings provide valuable insights for preventing and reducing such serious complications.

**INTRODUCTION**

Endoscopic ultrasound-guided minimally invasive tissue acquisition can be mainly performed by two approaches as follows: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB). Such procedures are safe and accurate to acquire tissue in the pancreas, abdomen, subepithelial masses, pelvis, and lymphoma. In EUS-FNA, the puncture needle is penetrated into the target lesion through the digestive tract under the monitoring of endoscopic ultrasound probe to obtain cell or tissue materials in order to determine the nature, origin, and pathological features of the lesion. Since its first introduction in the 1990s, EUS-FNA has become the standard sampling approach for suspected intra-abdominal and intrathoracic lesions (various masses and lymph node tissues) due to its high accuracy[1] and low complication rate[2], which can further provide staging and diagnostic information[3-6]. It has been reported that the incidence of post-EUS-FNA surgical complications, such as infection, acute pancreatitis, bleeding, and duodenal perforation, ranges from 0.98% to 3.4%[7-9]. However, a technology-related limitation of FNA is the scant cellularity and lack of histological structure provided in samples, leading to the difficulty of diagnosis[10,11]. To overcome these shortcomings, EUS-FNB has been developed. It uses a new type of needle with micro-core acquisition technology, which can obtain histological core samples and cytological aspirates at the same time, achieving a diagnostic sensitivity and specificity > 90%[12-15]. Studies have shown that the number of passes, diagnostic accuracy, and histological yield of EUS-FNB are better compared with those of EUS-FNA[16,17]. Both FNA and FNB are considered relatively safe in most cases, and EUS uses a shorter needle track, which may lead to a lower possibility of needle tract seeding[7,18]. The estimated prevalence of needle tract seeding of FNA is 0.003%-0.009%[2]. Recently, increasing case reports of needle tract seeding following EUS-FNA or EUS-FNB are emerging, especially in the diagnosis of pancreatic cancer[19,20]. In the present work, we integrated these case reports and the related literature, and summarized the relevant cases and technical characteristics of needle tract seeding. Collectively, our findings provided valuable insights into the prevention and reduction of such serious complication.

**METHODS**

PubMed, Medline ,and Cochrane Library were searched to identify articles published between June 1996 and January 2020 using the search items as follows: “Endoscopic ultrasound (EUS)”, “fine needle aspiration (FNA)”, “fine needle biopsy (FNB)”, “needle tract seeding”, and “seeding”. A total of 140 potentially relevant articles were identified from our initial search, 94 of which were excluded after reviewing the abstracts and titles. Finally, 46 articles focusing on EUS-FNA or EUS-FNB related complications met our inclusion criteria, including 34 case reports about needle tract seeding following EUS-FNA or EUS-FNB.

**EUS-FNA- OR EUS-FNB-INDUCED NEEDLE TRACT SEEDING**

According to related reports, the incidence of tumor seeding ranges from 0.005% to 0.009% in percutaneous FNA of gastrointestinal tract (GI) and adjacent organic lesions guided by external ultrasound or computed tomography (CT)[21]. Furthermore, a previously published retrospective study consisting of 73 patients submitted to pancreatic mass FNA has reported that the incidence of needle tract seeding is as high as 1.4%[22]. In recent years, studies have shown that the total complication rate of EUS-FNA varies from 0.5% to 3%[13,23,24]. One of the more serious complications following EUS-FNA is tumor seeding, which can lead to the development of peritoneal carcinomatosis and recurrence along the needle tract. Due to the shorter puncture path under the guidance of EUS, the incidence of tumor seeding is considered to be much lower compared with that of the percutaneous FNA[18]. In previous case reports[25-28], the location of the recurrent tumor appearing in the gastric wall is very close to the previous FNA puncture site, supporting the hypothesis that the tumor may spread along the needle track following EUS-FNA. As for EUS-FNB, previous studies have reported that it has a comparable adverse event rate (varied between 0-7.8%) to EUS-FNA[29-33], and the recurrence due to needle tract seeding after EUS-FNB is also considered a rare event. Recently, Kawabata *et al*[34] have reported a case of tumor seeding caused by EUS-FNB.

On the contrary, there are some reports revealing that preoperative EUS-FNA for patients with pancreatic cancer does not affect the postoperative survival, needle tract seeding, or peritoneal recurrence[35-39]. For example, Yane *et al*[40] have assessed whether preoperative EUS-FNA in patients with pancreatic cancer increases the risk of stomach or peritoneal recurrence, and whether it affects the patient’s recurrence-free survival and overall survival in a retrospective study. In this retrospective study, there were 301 patients undergoing distal pancreatectomy due to invasive pancreatic cancer from January 2006 to December 2015. A total of 176 patients received preoperative EUS-FNA, and 34 patients had a peritoneal recurrence (including 18 patients in the non-EUS-FNA group and 16 patients in the EUS-FNA group). Multivariate analysis did not find a significant correlation between the preoperative EUS-FNA and recurrence of stomach or peritoneal tumors[40]. To date, similar results have been obtained in the other eight retrospective studies[8,35,36,38,39,41-43]. In these studies, preoperative EUS-FNA has no negative impact on the survival of patients with pancreatic cancer and does not lead to tumor seeding through the needle tract.

However, it has been suggested that the risk of needle tract seeding following EUS-FNA or EUS-FNB is underestimated. First, most studies are single-center studies with a relatively small number of patients. Therefore, it is impossible to accurately estimate the incidence of needle tract seeding. Second, it is generally believed that it is difficult to diagnose low-volume gastric or peritoneal metastases clinically, because not all patients undergo the same strict diagnostic follow-up after surgery. Third, the follow-up period is relatively short, and thus the patients with unresectable tumors die before the clinical evidence of tumor spreading. Fourth, a preoperative biopsy may lead to the deposition of cancer cells outside the surgical resection area, which mistakenly classifies the cancer cell growth as a tumor recurrence or incomplete resection. In summary, these characteristics may lead to a significant reduction in the prediction of the number and location of cancer recurrence.

In a prospective study[44], 140 patients underwent lumen fluid aspiration before and after FNA through the suction channel and underwent cytological analysis during EUS. The cytological examination of intraluminal fluid showed that the positive rate of malignant tumors in patients with intraluminal tumor was 48%. This is a normal phenomenon, because cancer cells in the GI may shed. However, what is puzzling is that three (11.5%) patients tested positive for post EUS-FNA luminal fluid cytology in 26 patients with pancreatic cancer (extraluminal cancer). Normally, these three cases of extraluminal cancer should not be positive in cytological examination of intraluminal fluid, because there is no reasonable explanation for the metastatic pathway that allows extraluminal cancer cells into intestinal cavity. Therefore, the post-FNA positive luminal fluid cytology may be related to FNA.

At present, EUS-FNA is performed on intraabdominal and intrathoracic tumors, and surgical resection of these lesions usually does not remove the needle tract site, which may lead to a rare phenomenon of tumor seeding after operation. The incidence of such seeding is significantly low, and published data are only found in case reports and literature reviews. Due to the deficiency of data, it is not possible to determine whether the tumor seeding is caused by the malignant potential of these tumors or a technical defect. In the future, we need to conduct multi-center, large-scale, prospective studies to fully determine the clinical characteristics of needle tract seeding following EUS-FNA and EUS-FNB.

**SUMMARY OF CASES ON NEEDLE TRACT SEEDING**

Since the first described case of EUS-FNA-induced needle tract seeding in a patient with intraductal papillary mucinous neoplasm in 2003[45], 33 patients with needle tract seeding following EUS-FNA or EUS-FNB have been reported up to January 2020. Of these cases, 27 were found in pancreatic cancer patients after EUS-FNA[19,20,25,27,28,36,40,46-58], one in a pancreatic cancer patient after EUS-FNB[34](Table 1), and five in patients with other intra-abdominal and intrathoracic tumors after EUS-FNA[59-63] (Table 2). A total of 29 cases with pancreatic body or pancreatic tail cancer had needle tract seeding caused by diagnostic FNA or FNB. Tumor seeding following FNA or FNB has not been reported in pancreatic head mass. A possible reason is that patients with pancreatic head lesions need to remove both the primary foci and pancreatico-duodenum (including the needle tract). Therefore, seeding is unlikely to be successful. In contrast, FNA or FNB is usually performed for pancreatic body/tail tumors through the transgastric approach without removing the needle tract during pancreatectomy. Therefore, if the surgical procedure fails to remove the needle tract, we should seriously consider the possibility of tumor seeding following FNA or FNB of resectable thoracoabdominal tumors.

This review included 33 patients (16 males, 17 females; mean age 68.2 ± 12.2 years). Regarding the seeding site, 30 cases (90.9%) in the gastric wall, two in the esophageal wall, and one in the gastroesophageal junction were found to have tumor implantation. Only 18 cases have reported the size of the seeding tumor, with a median of 25 mm (range, 4-50 mm). Most seeding tumors were mainly located in the submucosal muscle layer or serous membrane layer of the GI, and thus they mainly appeared as submucosal tumor-like masses.

In terms of the FNA/FNB procedure, 25 (75.8%) cases used 22-G puncture needle during the execution of surgery, and the puncture process in two cases were not described. In most cases, a syringe was used for vacuum suction during the puncture process. The average number of needle pass was 2.8 ± 1.0.

As for the treatment of EUS-FNA or FNB-related needle tract seeding, chemotherapy has been performed in four cases, and the patients died at 10.8 mo, 12 mo, 26 mo, and 2 years, respectively, after chemotherapy. Surgical resection was selected in 21 cases, of which eight were followed for an average of 23.2 mo without tumor recurrence, three died about 20 mo after surgery, and detailed results and follow-up information are not obtained from the other ten cases undergoing surgical resection. In one case of tumor seeding in the esophageal wall, the lesion disappeared at 2 mo after radiation therapy[60]. In one case receiving surgery and chemotherapy at the same time, no tumor recurred after 6 years of follow-up[20]. There are no reports for the treatment methods for the remaining six cases. Additionally, Iida *et al*[26] have reported that a patient with pancreatic cancer had an EUS-FNA-related tumor seeding on the lower posterior gastric wall. At 21 mo after distal gastrectomy, a recurrent lesion was found on the upper posterior gastric wall. The author has suggested that the patient should undergo total gastrectomy rather than simple surgical resection[26]. Based on the above-mentioned results, the long-term prognosis of simple surgical resection of seeding tumors remains unclear. It is possible that radical surgery in combination with chemotherapy can improve the prognosis.

In these 33 case reports, the discovering process of seeding tumors also greatly varies. A total of 13 (39.3%) cases had abnormalities detected during regular CT/positron emission tomography-computed tomography (PET-CT) examinations, seven (21.2%) had clinical symptoms and received further examination, four (12.1%) showed a submucosal mass by regular esophagogastroduodenoscopy examination, six (18.2%) were found to have elevated CA19-9 levels and underwent further examination, and three (9.1%) were accidentally discovered during the operation. In addition, the interval time from EUS-FNA or EUS-FNB to detection of needle tract seeding greatly varies, with a median interval of 22 mo (range, 1-67 mo).

Since most seeding tumors are located in the gastric submucosal layer, it may be difficult to detect these early lesions by gastroscopy unless they are large enough to form a raised mass that can be visualized *via* gastroscopy. Paquin *et al*[46] have reported that a 3 cm mass was found on the stomach wall by EUS. However, endoscopy revealed a normal gastric mucosa without ulcers or other abnormalities[46]. If tumor seeding is suspected in the GI, EUS may be useful in the early detection of these lesions, while the predicted probability may be too low to be cost-effective in most cases. Since EUS-FNA or EUS-FNB is more commonly used in the diagnosis of pancreatic diseases, most cases of tumor seeding are related to pancreatic tumors. Early detection is significantly crucial for needle tract seeding by surgical procedures. Of the 28 pancreatic cancer patients included in this review, 23 (82.2%) had no clinical symptoms at the time of recurrence. On the contrary, ten of these patients underwent CA19-9 testing, and eight (80.0%) exhibited increased CA19-9 levels. Therefore, during postoperative follow-up, CA19-9 may be helpful for the early detection of seeding recurrence. In addition, research shows that changes in the levels of CA19-9 are frequently more than 6 mo earlier than radiological recurrence in patients with pancreatic cancer[64]. In addition, PET-CT represents a more sensitive approach compared with the traditional imaging methods (CT and magnetic resonance imaging [MRI]), and it is also used for the early detection of tumor recurrence after pancreatic cancer surgery[65,66]. Six (100%) cases receiving PET showed that the seeding tumors increased the uptake of fluorodeoxyglucose. However, PET/CT examinations are usually just to clarify the unclear manifestations of CT and MRI.

According to this review, the best treatment method and detection strategy for needle tract seeding have not yet been clarified at present. Among these cases, some patients achieved a good prognosis after surgery[50,52]. However, some reports have shown that the delayed discovery of needle tract seeding has caused metastases in both the stomach wall and lymph nodes[48]. In addition, it has been reported that re-recurrence occurred after partial gastrectomy due to gastric wall metastasis caused by needle tract seeding[26]. Therefore, early diagnosis and surgical resection of these lesions are an effective method for patients with needle tract seeding after EUS-FNA or EUS-FNB to achieve a long-term survival. Moreover, the examination of CA19-9, endoscopy, and imaging modalities (especially PET-CT) may be of great significance for the early detection of tumor recurrence along needle tract.

**RISK FACTORS AND PREVENTION STRATEGIES FOR NEEDLE TRACT SEEDING**

It has been previously thought that several factors, such as the number of punctures, needle size, needle movement, and tumor characteristics (cystic tumors or poorly differentiated tumors) may affect the development of seeding[50,60,62]. However, due to the small number of reported cases of tumor seeding, it remains unknown whether tumor factors or FNA/FNB procedures are significantly correlated with the occurrence of needle tract seeding. Sakamoto *et al*[55] have conducted an experiment using an agar model, and they considered that the slow-pull technique and the use of puncture needle with a side hole may result in needle tract seeding. Although these results may not reflect the actual clinical situations, it also gives us a warning.

As a rare but serious complication, needle tract seeding following EUS-FNA or EUS-FNB may worsen the prognosis of patients. Therefore, several strategies have been proposed to reduce the tumor seeding. Yane *et al*[40] have reported that EUS-FNA should only be used in patients requiring a pathological diagnosis to develop more accurate treatment strategies (for example, patients with pancreatic cancer who are scheduled to undergo preoperative neoadjuvant therapy or difficult to diagnose by imaging). In addition, the distance between the endoscope and the target site should be as short as possible[67]. Tomonari *et al*[25] has suggested that if the surgical resection does not include puncture needle tract or puncture results cannot change treatment options, EUS-FNA should be avoided or the number of puncture should be limited[25,67]. Therefore, we can consider replacing EUS-FNA with EUS-FNB to diagnose suspected intra-abdominal and intrathoracic lesions. Because some studies have shown that the FNB needle can produce more accurate diagnoses, a better histological yield, and a lower number of passes compared with the FNA needle[17,68]. This is probably a change which will impact also the already low rate of seeding. Moreover, only one case of needle tract seeding following FNB has been reported so far. Tyagi and Dey believed that a puncture needle with a covering sleeve should be used to avoid the needle tract seeding[69].

As the needle site is not within the scope of surgical resection, we should carefully consider the risk-benefit ratio of EUS-FNA or EUS-FNB. If we perform puncture and early radical resection in this situation, regular detection of blood tumor markers, imaging, and endoscopy are essential. Moreover, it has been suggested that neoadjuvant chemotherapy can provide survival benefits for patients with resectable pancreatic cancer[70].

**CONCLUSION**

More than 25 years after its introduction, endoscopic ultrasound-guided minimally invasive tissue acquisition has replaced percutaneous FNA guided by external ultrasound or CT. Due to its higher effectiveness and lower complications, it has achieved a crucial role in the diagnosis of GI and adjacent organic lesions. Although needle tract seeding following EUS-FNA or EUS-FNB is a rare and easily ignored complication, it can bring serious consequences to patients. Endosonographers should determine the indications for surgery according to the characteristics of different cases. If the location of the needle tract is not within the scope of surgical resection, we should be aware of the risk of tumor metastasis along the needle tract following EUS-FNA or EUS-FNB. We should also pay attention to several aspects, such as shortening the puncture path, limiting the number of puncture, paying attention to the procedure method, and adding seeding needle sleeve. For example, EUS-FNB has greatly improved the diagnostic efficacy of EUS guided tissue acquisition with fewer passes so that we may consider replacing EUS-FNA with EUS-FNB to diagnose suspected intra-abdominal and intrathoracic lesions. In addition, regular detection of blood tumor markers, imaging, and endoscopy are required to diagnose tumor seeding at an early stage. Furthermore, it is necessary to accumulate more cases of needle tract seeding and conduct a large-scale prospective cohort study to confirm its detailed clinical characteristics in order to actively prevent or early detect the risk of needle tract seeding.

**REFERENCES**

1 **Eloubeidi MA**, Varadarajulu S, Desai S, Shirley R, Heslin MJ, Mehra M, Arnoletti JP, Eltoum I, Wilcox CM, Vickers SM. A prospective evaluation of an algorithm incorporating routine preoperative endoscopic ultrasound-guided fine needle aspiration in suspected pancreatic cancer. *J Gastrointest Surg* 2007; **11**: 813-819 [PMID: 17440790 DOI: 10.1007/s11605-007-0151-x]

2 **Jenssen C**, Alvarez-Sánchez MV, Napoléon B, Faiss S. Diagnostic endoscopic ultrasonography: assessment of safety and prevention of complications. *World J Gastroenterol* 2012; **18**: 4659-4676 [PMID: 23002335 DOI: 10.3748/wjg.v18.i34.4659]

3 **Kurita A**, Kodama Y, Nakamoto Y, Isoda H, Minamiguchi S, Yoshimura K, Kuriyama K, Sawai Y, Uza N, Hatano E, Uemoto S, Togashi K, Haga H, Chiba T. Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer. *Gastrointest Endosc* 2016; **84**: 467-475.e1 [PMID: 26970011 DOI: 10.1016/j.gie.2016.02.045]

4 **Ende AR**, Sedarat A, Shah P, Jhala N, Fraker DL, Drebin JA, Metz DC, Kochman ML. Risk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration. *Endosc Ultrasound* 2016; **5**: 49-54 [PMID: 26879167 DOI: 10.4103/2303-9027.175897]

5 **Chin YK**, Iglesias-Garcia J, de la Iglesia D, Lariño-Noia J, Abdulkader-Nallib I, Lázare H, Rebolledo Olmedo S, Dominguez-Muñoz JE. Accuracy of endoscopic ultrasound-guided tissue acquisition in the evaluation of lymph nodes enlargement in the absence of on-site pathologist. *World J Gastroenterol* 2017; **23**: 5755-5763 [PMID: 28883701 DOI: 10.3748/wjg.v23.i31.5755]

6 **Yamao K**, Ohashi K, Mizutani S, Furukawa T, Watanabe Y, Nakamura T, Suzuki T, Takeda K. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the diagnosis of digestive diseases. *Endoscopy* 1998; **30 Suppl 1**: A176-A178 [PMID: 9765119 DOI: 10.1055/s-2007-1001513]

7 **Wang KX**, Ben QW, Jin ZD, Du YQ, Zou DW, Liao Z, Li ZS. Assessment of morbidity and mortality associated with EUS-guided FNA: a systematic review. *Gastrointest Endosc* 2011; **73**: 283-290 [PMID: 21295642 DOI: 10.1016/j.gie.2010.10.045]

8 **Tsutsumi H**, Hara K, Mizuno N, Hijioka S, Imaoka H, Tajika M, Tanaka T, Ishihara M, Yoshimura K, Shimizu Y, Niwa Y, Sasaki Y, Yamao K. Clinical impact of preoperative endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma. *Endosc Ultrasound* 2016; **5**: 94-100 [PMID: 27080607 DOI: 10.4103/2303-9027.180472]

9 **Katanuma A**, Maguchi H, Yane K, Hashigo S, Kin T, Kaneko M, Kato S, Kato R, Harada R, Osanai M, Takahashi K, Nojima M. Factors predictive of adverse events associated with endoscopic ultrasound-guided fine needle aspiration of pancreatic solid lesions. *Dig Dis Sci* 2013; **58**: 2093-2099 [PMID: 23423501 DOI: 10.1007/s10620-013-2590-4]

10 **Philipper M**, Hollerbach S, Gabbert HE, Heikaus S, Böcking A, Pomjanski N, Neuhaus H, Frieling T, Schumacher B. Prospective comparison of endoscopic ultrasound-guided fine-needle aspiration and surgical histology in upper gastrointestinal submucosal tumors. *Endoscopy* 2010; **42**: 300-305 [PMID: 20306384 DOI: 10.1055/s-0029-1244006]

11 **Levy MJ**, Wiersema MJ. EUS-guided Trucut biopsy. *Gastrointest Endosc* 2005; **62**: 417-426 [PMID: 16111962 DOI: 10.1016/j.gie.2005.04.044]

12 **DeWitt J**, Cho CM, Lin J, Al-Haddad M, Canto MI, Salamone A, Hruban RH, Messallam AA, Khashab MA. Comparison of EUS-guided tissue acquisition using two different 19-gauge core biopsy needles: a multicenter, prospective, randomized, and blinded study. *Endosc Int Open* 2015; **3**: E471-E478 [PMID: 26528504 DOI: 10.1055/s-0034-1392222]

13 **Iglesias-Garcia J**, Poley JW, Larghi A, Giovannini M, Petrone MC, Abdulkader I, Monges G, Costamagna G, Arcidiacono P, Biermann K, Rindi G, Bories E, Dogloni C, Bruno M, Dominguez-Muñoz JE. Feasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study. *Gastrointest Endosc* 2011; **73**: 1189-1196 [PMID: 21420083 DOI: 10.1016/j.gie.2011.01.053]

14 **Levy MJ**. Endoscopic ultrasound-guided trucut biopsy of the pancreas: prospects and problems. *Pancreatology* 2007; **7**: 163-166 [PMID: 17592229 DOI: 10.1159/000104240]

15 **Chen G**, Liu S, Zhao Y, Dai M, Zhang T. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a meta-analysis. *Pancreatology* 2013; **13**: 298-304 [PMID: 23719604 DOI: 10.1016/j.pan.2013.01.013]

16 **van Riet PA**, Larghi A, Attili F, Rindi G, Nguyen NQ, Ruszkiewicz A, Kitano M, Chikugo T, Aslanian H, Farrell J, Robert M, Adeniran A, Van Der Merwe S, Roskams T, Chang K, Lin F, Lee JG, Arcidiacono PG, Petrone M, Doglioni C, Iglesias-Garcia J, Abdulkader I, Giovannini M, Bories E, Poizat F, Santo E, Scapa E, Marmor S, Bucobo JC, Buscaglia JM, Heimann A, Wu M, Baldaque-Silva F, Moro CF, Erler NS, Biermann K, Poley JW, Cahen DL, Bruno MJ. A multicenter randomized trial comparing a 25-gauge EUS fine-needle aspiration device with a 20-gauge EUS fine-needle biopsy device. *Gastrointest Endosc* 2019; **89**: 329-339 [PMID: 30367877 DOI: 10.1016/j.gie.2018.10.026]

17 **Cheng B**, Zhang Y, Chen Q, Sun B, Deng Z, Shan H, Dou L, Wang J, Li Y, Yang X, Jiang T, Xu G, Wang G. Analysis of Fine-Needle Biopsy versus Fine-Needle Aspiration in Diagnosis of Pancreatic and Abdominal Masses: A Prospective, Multicenter, Randomized Controlled Trial. *Clin Gastroenterol Hepatol* 2018; **16**: 1314-1321 [PMID: 28733257 DOI: 10.1016/j.cgh.2017.07.010]

18 **Micames C**, Jowell PS, White R, Paulson E, Nelson R, Morse M, Hurwitz H, Pappas T, Tyler D, McGrath K. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA versus percutaneous FNA. *Gastrointest Endosc* 2003; **58**: 690-695 [PMID: 14595302 DOI: 10.1016/s0016-5107(03)02009-1]

19 **Sato N**, Takano S, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Suzuki D, Sakai N, Kagawa S, Mishima T, Nakadai E, Mikata R, Kato N, Ohtsuka M. Needle tract seeding recurrence of pancreatic cancer in the gastric wall with paragastric lymph node metastasis after endoscopic ultrasound-guided fine needle aspiration followed by pancreatectomy: a case report and literature review. *BMC Gastroenterol* 2020; **20**: 13 [PMID: 31941458 DOI: 10.1186/s12876-020-1159-x]

20 **Rothermel LD**, Strosberg C, Centeno BA, Malafa MP. Case Report of Isolated Gastric Metastasis of Pancreatic Cancer From a Diagnostic Biopsy: Management of a Rare Oncologic Entity. *Cancer Control* 2020; **27**: 1073274820904042 [PMID: 32107943 DOI: 10.1177/1073274820904042]

21 **Smith EH**. Complications of percutaneous abdominal fine-needle biopsy. Review. *Radiology* 1991; **178**: 253-258 [PMID: 1984314 DOI: 10.1148/radiology.178.1.1984314]

22 **Kosugi C**, Furuse J, Ishii H, Maru Y, Yoshino M, Kinoshita T, Konishi M, Nakagohri T, Inoue K, Oda T. Needle tract implantation of hepatocellular carcinoma and pancreatic carcinoma after ultrasound-guided percutaneous puncture: clinical and pathologic characteristics and the treatment of needle tract implantation. *World J Surg* 2004; **28**: 29-32 [PMID: 14648043 DOI: 10.1007/s00268-003-7003-y]

23 **Bang JY**, Hebert-Magee S, Navaneethan U, Hasan MK, Hawes R, Varadarajulu S. Randomized trial comparing the Franseen and Fork-tip needles for EUS-guided fine-needle biopsy sampling of solid pancreatic mass lesions. *Gastrointest Endosc* 2018; **87**: 1432-1438 [PMID: 29305893 DOI: 10.1016/j.gie.2017.11.036]

24 **Tharian B**, Tsiopoulos F, George N, Pietro SD, Attili F, Larghi A. Endoscopic ultrasound fine needle aspiration: Technique and applications in clinical practice. *World J Gastrointest Endosc* 2012; **4**: 532-544 [PMID: 23293723 DOI: 10.4253/wjge.v4.i12.532]

25 **Tomonari A**, Katanuma A, Matsumori T, Yamazaki H, Sano I, Minami R, Sen-yo M, Ikarashi S, Kin T, Yane K, Takahashi K, Shinohara T, Maguchi H. Resected tumor seeding in stomach wall due to endoscopic ultrasonography-guided fine needle aspiration of pancreatic adenocarcinoma. *World J Gastroenterol* 2015; **21**: 8458-8461 [PMID: 26217099 DOI: 10.3748/wjg.v21.i27.8458]

26 **Iida T**, Adachi T, Ohe Y, Nakagaki S, Yabana T, Kondo Y, Nakase H. Re-recurrence after distal gastrectomy for recurrence caused by needle tract seeding during endoscopic ultrasound-guided fine-needle aspiration of a pancreatic adenocarcinoma. *Endoscopy* 2016; **48**: E304-E305 [PMID: 27669534 DOI: 10.1055/s-0042-116431]

27 **Katanuma A**, Maguchi H, Hashigo S, Kaneko M, Kin T, Yane K, Kato R, Kato S, Harada R, Osanai M, Takahashi K, Shinohara T, Itoi T. Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. *Endoscopy* 2012; **44 Suppl 2 UCTN**: E160-E161 [PMID: 22622721 DOI: 10.1055/s-0031-1291716]

28 **Yamaguchi H**, Morisaka H, Sano K, Nagata K, Ryozawa S, Okamoto K, Ichikawa T. Seeding of a Tumor in the Gastric Wall after Endoscopic Ultrasound-guided Fine-needle Aspiration of Solid Pseudopapillary Neoplasm of the Pancreas. *Intern Med* 2020; **59**: 779-782 [PMID: 31787691 DOI: 10.2169/internalmedicine.3244-19]

29 **Ishikawa T**, Kawashima H, Ohno E, Tanaka H, Sakai D, Iida T, Nishio R, Yamamura T, Furukawa K, Nakamura M, Miyahara R, Hashimoto S, Ishigami M, Hirooka Y. Clinical Impact of EUS-Guided Fine Needle Biopsy Using a Novel Franseen Needle for Histological Assessment of Pancreatic Diseases. *Can J Gastroenterol Hepatol* 2019; **2019**: 8581743 [PMID: 30854353 DOI: 10.1155/2019/8581743]

30 **Yang Y**, Li L, Qu C, Liang S, Zeng B, Luo Z. Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions: a systematic review and Meta-Analysis. *Sci Rep* 2016; **6**: 22978 [PMID: 26960914 DOI: 10.1038/srep22978]

31 **Armellini E**, Manfrin E, Trisolini E, Andorno S, Ballarè M, Bernardoni L, Boldorini RL, Gabbrielli A, Frulloni L, Larghi A, Occhipinti P, Scarpa A, Crinò SF. Histologic retrieval rate of a newly designed side-bevelled 20G needle for EUS-guided tissue acquisition of solid pancreatic lesions. *United European Gastroenterol J* 2019; **7**: 96-104 [PMID: 30788121 DOI: 10.1177/2050640618804443]

32 **Inoue T**, Okumura F, Sano H, Mizushima T, Tsukamoto H, Fujita Y, Ibusuki M, Kitano R, Kobayashi Y, Ishii N, Ito K, Yoneda M. Impact of endoscopic ultrasound-guided fine-needle biopsy on the diagnosis of subepithelial tumors: A propensity score-matching analysis. *Dig Endosc* 2019; **31**: 156-163 [PMID: 30171772 DOI: 10.1111/den.13269]

33 **El Hajj II**, Wu H, Reuss S, Randolph M, Harris A, Gromski MA, Al-Haddad M. Prospective Assessment of the Performance of a New Fine Needle Biopsy Device for EUS-Guided Sampling of Solid Lesions. *Clin Endosc* 2018; **51**: 576-583 [PMID: 30001616 DOI: 10.5946/ce.2018.053]

34 **Kawabata H**, Miyazawa Y, Sato H, Okada T, Hayashi A, Iwama T, Fujibayashi S, Goto T, Sasajima J, Takauji S, Fujiya M, Torimoto Y, Tanino M, Omori Y, Ono Y, Karasaki H, Mizukami Y, Okumura T. Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB. *Endosc Int Open* 2019; **7**: E1768-E1772 [PMID: 31828215 DOI: 10.1055/a-1034-7700]

35 **Kim SH**, Woo YS, Lee KH, Lee JK, Lee KT, Park JK, Kang SH, Kim JW, Park JK, Park SW. Preoperative EUS-guided FNA: effects on peritoneal recurrence and survival in patients with pancreatic cancer. *Gastrointest Endosc* 2018; **88**: 926-934 [PMID: 29981302 DOI: 10.1016/j.gie.2018.06.024]

36 **Ngamruengphong S**, Xu C, Woodward TA, Raimondo M, Stauffer JA, Asbun HJ, Wallace MB. Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided fine needle aspiration. *Endoscopy* 2013; **45**: 619-626 [PMID: 23881804 DOI: 10.1055/s-0033-1344216]

37 **Yoon WJ**, Daglilar ES, Fernández-del Castillo C, Mino-Kenudson M, Pitman MB, Brugge WR. Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: the PIPE Study. *Endoscopy* 2014; **46**: 382-387 [PMID: 24619804 DOI: 10.1055/s-0034-1364937]

38 **Ngamruengphong S**, Swanson KM, Shah ND, Wallace MB. Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer. *Gut* 2015; **64**: 1105-1110 [PMID: 25575893 DOI: 10.1136/gutjnl-2014-307475]

39 **Ikezawa K**, Uehara H, Sakai A, Fukutake N, Imanaka K, Ohkawa K, Tanakura R, Ioka T, Tanaka S, Ishikawa O, Katayama K. Risk of peritoneal carcinomatosis by endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. *J Gastroenterol* 2013; **48**: 966-972 [PMID: 23065024 DOI: 10.1007/s00535-012-0693-x]

40 **Yane K**, Kuwatani M, Yoshida M, Goto T, Matsumoto R, Ihara H, Okuda T, Taya Y, Ehira N, Kudo T, Adachi T, Eto K, Onodera M, Sano I, Nojima M, Katanuma A. Non-negligible rate of needle tract seeding after endoscopic ultrasound-guided fine-needle aspiration for patients undergoing distal pancreatectomy for pancreatic cancer. *Dig Endosc* 2019; Online ahead of print [PMID: 31876309 DOI: 10.1111/den.13615]

41 **Kudo T**, Kawakami H, Kuwatani M, Eto K, Kawahata S, Abe Y, Onodera M, Ehira N, Yamato H, Haba S, Kawakubo K, Sakamoto N. Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance. *World J Gastroenterol* 2014; **20**: 3620-3627 [PMID: 24707146 DOI: 10.3748/wjg.v20.i13.3620]

42 **Beane JD**, House MG, Coté GA, DeWitt JM, Al-Haddad M, LeBlanc JK, McHenry L, Sherman S, Schmidt CM, Zyromski NJ, Nakeeb A, Pitt HA, Lillemoe KD. Outcomes after preoperative endoscopic ultrasonography and biopsy in patients undergoing distal pancreatectomy. *Surgery* 2011; **150**: 844-853 [PMID: 22000199 DOI: 10.1016/j.surg.2011.07.068]

43 **Zhu H**, Jiang F, Zhu J, Du Y, Jin Z, Li Z. Assessment of morbidity and mortality associated with endoscopic ultrasound-guided fine-needle aspiration for pancreatic cystic lesions: A systematic review and meta-analysis. *Dig Endosc* 2017; **29**: 667-675 [PMID: 28218999 DOI: 10.1111/den.12851]

44 **Levy MJ**, Gleeson FC, Campion MB, Caudill JL, Clain JE, Halling K, Rajan E, Topazian MD, Wang KK, Wiersema MJ, Clayton A. Prospective cytological assessment of gastrointestinal luminal fluid acquired during EUS: a potential source of false-positive FNA and needle tract seeding. *Am J Gastroenterol* 2010; **105**: 1311-1318 [PMID: 20197762 DOI: 10.1038/ajg.2010.80]

45 **Hirooka Y**, Goto H, Itoh A, Hashimoto S, Niwa K, Ishikawa H, Okada N, Itoh T, Kawashima H. Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. *J Gastroenterol Hepatol* 2003; **18**: 1323-1324 [PMID: 14535994 DOI: 10.1046/j.1440-1746.2003.03040.x]

46 **Paquin SC**, Gariépy G, Lepanto L, Bourdages R, Raymond G, Sahai AV. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. *Gastrointest Endosc* 2005; **61**: 610-611 [PMID: 15812422 DOI: 10.1016/s0016-5107(05)00082-9]

47 **Chong A**, Venugopal K, Segarajasingam D, Lisewski D. Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia. *Gastrointest Endosc* 2011; **74**: 933-935 [PMID: 21951481 DOI: 10.1016/j.gie.2010.10.020]

48 **Ahmed K**, Sussman JJ, Wang J, Schmulewitz N. A case of EUS-guided FNA-related pancreatic cancer metastasis to the stomach. *Gastrointest Endosc* 2011; **74**: 231-233 [PMID: 21168837 DOI: 10.1016/j.gie.2010.10.008]

49 **Sakurada A**, Hayashi T, Ono M, Ishiwatari H, Ogino J, Kimura Y, Kato J. A case of curatively resected gastric wall implantation of pancreatic cancer caused by endoscopic ultrasound-guided fine-needle aspiration. *Endoscopy* 2015; **47 Suppl 1 UCTN**: E198-E199 [PMID: 26062146 DOI: 10.1055/s-0034-1377592]

50 **Minaga K**, Kitano M, Yamashita Y. Surgically resected needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration in pancreatic cancer. *J Hepatobiliary Pancreat Sci* 2015; **22**: 708-709 [PMID: 26084566 DOI: 10.1002/jhbp.269]

51 **Yamabe A**, Irisawa A, Shibukawa G, Hoshi K, Fujisawa M, Igarashi R, Sato A, Maki T, Hojo H. Rare condition of needle tract seeding after EUS-guided FNA for intraductal papillary mucinous carcinoma. *Endosc Int Open* 2016; **4**: E756-E758 [PMID: 27556091 DOI: 10.1055/s-0042-107072]

52 **Minaga K**, Kitano M, Enoki E, Kashida H, Kudo M. Needle-Tract Seeding on the Proximal Gastric Wall After EUS-Guided Fine-Needle Aspiration of a Pancreatic Mass. *Am J Gastroenterol* 2016; **111**: 1515 [PMID: 27808133 DOI: 10.1038/ajg.2016.307]

53 **Iida T**, Adachi T, Nakagaki S, Yabana T, Goto A, Kondo Y, Watanabe Y, Kasai K. EDUCATION AND IMAGING. Gastrointestinal: Needle tract implantation after endoscopic ultrasound-guided fine-needle aspiration of a pancreatic adenocarcinoma. *J Gastroenterol Hepatol* 2016; **31**: 285 [PMID: 26510538 DOI: 10.1111/jgh.13209]

54 **Kita E**, Yamaguchi T, Sudo K. A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomography/CT. *Gastrointest Endosc* 2016; **84**: 869-870 [PMID: 26853299 DOI: 10.1016/j.gie.2016.01.060]

55 **Sakamoto U**, Fukuba N, Ishihara S, Sumi S, Okada M, Sonoyama H, Ohshima N, Moriyama I, Kawashima K, Kinoshita Y. Postoperative recurrence from tract seeding after use of EUS-FNA for preoperative diagnosis of cancer in pancreatic tail. *Clin J Gastroenterol* 2018; **11**: 200-205 [PMID: 29392646 DOI: 10.1007/s12328-018-0822-z]

56 **Matsumoto K**, Kato H, Tanaka N, Okada H. Preoperative Detection of Tumor Seeding after Endoscopic Ultrasonography-guided Fine Needle Aspiration for Pancreatic Cancer. *Intern Med* 2018; **57**: 1797-1798 [PMID: 29434140 DOI: 10.2169/internalmedicine.0321-17]

57 **Yasumoto M**, Okabe Y, Ishikawa H, Kisaki J, Akiba J, Naito Y, Ishida Y, Ushijima T, Tsuruta O, Torimura T. A case of gastric wall implantation caused by EUS-FNA 22 mo after pancreatic cancer resection. *Endosc Ultrasound* 2018; **7**: 64-66 [PMID: 29451172 DOI: 10.4103/eus.eus\_58\_17]

58 **Matsui T**, Nishikawa K, Yukimoto H, Katsuta K, Nakamura Y, Tanaka S, Oiwa M, Nakahashi H, Shomi Y, Haruki Y, Taniguchi K, Shimomura M, Isaji S. Needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a report of two cases. *World J Surg Oncol* 2019; **17**: 134 [PMID: 31382964 DOI: 10.1186/s12957-019-1681-x]

59 **Shah JN**, Fraker D, Guerry D, Feldman M, Kochman ML. Melanoma seeding of an EUS-guided fine needle track. *Gastrointest Endosc* 2004; **59**: 923-924 [PMID: 15173817 DOI: 10.1016/s0016-5107(04)00340-2]

60 **Doi S**, Yasuda I, Iwashita T, Ibuka T, Fukushima H, Araki H, Hirose Y, Moriwaki H. Needle tract implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal lymphadenopathy. *Gastrointest Endosc* 2008; **67**: 988-990 [PMID: 18279861 DOI: 10.1016/j.gie.2007.10.025]

61 **Anderson B**, Singh J, Jafri SF. Tumor seeding following endoscopic ultrasonography-guided fine-needle aspiration of a celiac lymph node. *Dig Endosc* 2013; **25**: 344-345 [PMID: 23490122 DOI: 10.1111/den.12057]

62 **Yokoyama K**, Ushio J, Numao N, Tamada K, Fukushima N, Kawarai Lefor A, Yamamoto H. Esophageal seeding after endoscopic ultrasound-guided fine-needle aspiration of a mediastinal tumor. *Endosc Int Open* 2017; **5**: E913-E917 [PMID: 28924599 DOI: 10.1055/s-0043-114662]

63 **Goel A**, Hon KCA, Chong A. Needle Tract Tumor Seeding Following Endoscopic Ultrasound-Guided Fine Needle Aspiration of Metastatic Squamous Cell Carcinoma. *Clin Gastroenterol Hepatol* 2018; **16**: A27-A28 [PMID: 28433784 DOI: 10.1016/j.cgh.2017.04.024]

64 **Rieser CJ**, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. *Ann Surg Oncol* 2018; **25**: 3483-3491 [PMID: 29786131 DOI: 10.1245/s10434-018-6521-7]

65 **Wang L**, Dong P, Wang W, Li M, Hu W, Liu X, Tian B. Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma. *Medicine (Baltimore)* 2020; **99**: e19504 [PMID: 32176094 DOI: 10.1097/MD.0000000000019504]

66 **Wang L**, Dong P, Wang WG, Tian BL. Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis. *Int J Surg* 2017; **46**: 119-125 [PMID: 28890410 DOI: 10.1016/j.ijsu.2017.09.003]

67 **Fujii LL**, Levy MJ. Basic techniques in endoscopic ultrasound-guided fine needle aspiration for solid lesions: Adverse events and avoiding them. *Endosc Ultrasound* 2014; **3**: 35-45 [PMID: 24949409 DOI: 10.4103/2303-9027.123006]

68 **Alkhateeb K**, Lee BB, Alatassi H, Sanders MA, Omer EM, McClave SA, Fraig M. Comparison between two types of needles for Endoscopic Ultrasound (EUS)-guided fine aspiration biopsy of pancreatic and upper gastrointestinal masses. *Diagn Cytopathol* 2020; **48**: 197-202 [PMID: 31850666 DOI: 10.1002/dc.24361]

69 **Tyagi R**, Dey P. Needle tract seeding: an avoidable complication. *Diagn Cytopathol* 2014; **42**: 636-640 [PMID: 24591300 DOI: 10.1002/dc.23137]

70 **Motoi F**, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). *Jpn J Clin Oncol* 2019; **49**: 190-194 [PMID: 30608598 DOI: 10.1093/jjco/hyy190]

**Footnotes**

**Conflict-of-interest statement:** The authors of this manuscript have no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 5, 2020

**First decision:** July 25, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Armellini E, Bordonaro M, Ferreira CN **S-Editor:** Gao CC **L-Editor:** Wang TQ **P-Editor:**

**Table 1 Characteristics of reported needle tract seeding of pancreatic cancer**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Age**  | **Sex** | **Pathological diagnosis**  | **Staging** | **Location** | **Size, mm** | **Initial treatment** | **Frequency of puncture** | **Needle gauge** | **Time interval**  | **Details of needle tract seeding** |
| **Discovery** | **Location** | **Maximum diameter (mm)** | **Treatment** | **Outcome** |
| Paquin *et al*[46] 2005 | 65 | Male | Adenocarcinoma  | T1N0M0 | Pt | 22 | DP | 5 | 22G | 21 mo | Symptom/CT/EUS/CA19-9 | Posterior gastric wall | 50 | CHE | Died 12 mo after CHE |
| Chong *et al*[47] 2011 | 55 | Female | Adenocarcinoma | T2N0M0 | Pt | 27 | DP | 2 | 22G | 26 mo | CA19-9/PET-CT/EUS/EGD | Posterior gastric wall | 40 | Unknown, incurable | Unknown |
| Ahmed *et al*[48] 2011 | 79 | Male | Adenocarcinoma | T2N0M0 | Pb | Unknown | Central pancreatectomy | Several times | Unknown | 39 mo | PET-CT/EUS/CT | Gastric wall | 45 | Total gastrectomy | Died with widely metastatic melanoma |
| Katanuma *et al*[27] 2012 | 68 | Female | Adenocarcinoma | T2N0M0 | Pb | 20 | DP | 4 | 22G | 22 mo | EGD/CT | Posterior gastric wall | Unknown | Surgery | Unknown |
| Ngamruengphong *et al*[36] 2013 | 66 | Male | Adenocarcinoma | Unknown | Pb/Pt | Unknown | Subtotal pancreatectomy and Chemoradiation  | 3 | 22G and 19G | 27 mo | Symptom/EGD/EUS-FNA | Gastric wall | Unknown | Unknown | Unknown |
| Ngamruengphong *et al*[36] 2013 | 77 | Female | Adenocarcinoma | Unknown | Pt | 40 | DP and PG | 3 | 19G | 26 mo | Symptom/EGD | Gastric wall | Unknown | Unknown | Unknown |
| Sakurada *et al*[49] 2015 | 87 | Female | Adenosquamous carcinoma | T2N0M0 | Pb | 25 | DP | Unknown | 22G | 19 mo | CA19-9/CT/EUS | Posterior gastric wall | 20 | PG | Unknown |
| Tomonari *et al*[25] 2015 | 78 | Male | Pancreatic adenocarcinoma | T3N0M0 | Pb | 20 | DP and CHE | 2 | 22G | 28 mo | CA19-9/EGD | Gastric wall | 32 | Subtotal gastrectomy | Unknown |
| Minaga *et al*[50] 2015 | 64 | Female | Moderately differentiated tubular adenocarcinoma | T3N0M0 | Pb | 20 | DP | 3 | 22G | 8 mo | CA19-9//EGD | Posterior gastric wall | 12 | PG | No recurrence after 27 mo of follow-up |
| Yamabe *et al*[51] 2016 | 75 | Male | Intraductal papillary mucinous carcinoma  | Unknown | Unknown | 30 | CHE | Unknown | 25G | 3 mo  | CT/EGD/EUS-FNA | Posterior gastric wall | 24 | Palliative CHE | Died 26 mo after CHE |
| Minaga *et al*[52], 2016 | 72 | Female | Well-differentiated tubular adenocarcinoma | T1N0M0 | Pb | 10 | DP | 3 | 22G | 24 mo | EGD | Posterior gastric wall | 30 | Gastrectomy | No recurrence after 18 mo of follow-up |
| Iida *et al*[53] 2016 | 78 | Female | Infiltrating pancreatic duct cancer  | T3N0M0 | Unknown | Unknown | DP | 3 | 22G | 6 mo | PET-CT/EGD/EUS | Posterior gastric wall | 18 | DG | No recurrence after 10 mo of follow-up |
| Kita *et al*[54] 2016 | 68 | Female | Adenocarcinoma | Unknown | Pb/Pt | Unknown | Radiation | 2 | 22G | 7 mo | PET-CT/EGD | Posterior gastric wall | Unknown | Unknown | Unknown |
| Sakamoto *et al*[55] 2018 | 50 | Male |  Invasive ductal carcinoma | T4N1M0 | Pt | 38 | DP and CHE | 2 | 22G | 24 mo | EGD/EUS | Posterior gastric wall | 20 | PG | Unknown |
| Matsumoto *et al*[56] 2018 | 50 | Male | Adenocarcinoma | Unknown | Pb | 35 | CHE | 3 | 21G | 8 mo | CT/EUS | Gastric wall | Unknown | DP and PG | Unknown |
| Yasumoto *et al*[57] 2018 | 78 | Female | Well-differentiated tubular adenocarcinoma  | T3N0M0 | Pb | 10 | DP and CHE | 3 | 25G | 22 mo | Symptom/EGD | Posterior gastric wall | Unknown | PG | Unknown |
| Matsui *et al*[58] 2019 | 68 | Female | Invasive ductal carcinoma | T1N1M0 | Pb | 15 | DP and PG | 4 | 22 G, 19 G, 20 G | 25 d | Operative finding/CA19-9 | Posterior gastric wall | Micro | PG | Died 18 mo after treatment due to peritoneal dissemination |
| Matsui *et al*[58] 2019 | 70 | Male | Invasive ductal carcinoma | T3N0M1 | Pb | 34 | DP and PG | 1 | 22G | 4 mo | Operative finding | Posterior gastric wall | Micro | PG | Stabled 18 mo after treatment |
| Yane *et al*[40]2019 | 66 | Female | Well differentiated invasive adenocarcinoma | T3N0M0 | Pt | Unknown | DP  | 4 | 22G | 19 mo | CT/EGD | Posterior gastric wall | Unknown | CHE | Died 10.8 mo after diagnosis |
| Yane *et al*[40] 2019 | 78 | Male | Poorly differentiated invasive adenocarcinoma | T3N0M0 | Pt | Unknown | DP  | 2 | 22G | 27 mo | CT/EGD | Posterior gastric wall | Unknown | PG | Died 24.9 mo after diagnosis |
| Yane *et al*[40] 2019 | 86 | Female | Poorly differentiated invasive adenocarcinoma | T2N0M0 | Pb | Unknown | DP  | 3 | 22G | 19 mo | CT/EGD | Posterior gastric wall | Unknown | PG | Alive 62.4 mo after diagnosis |
| Yane *et al*[40] 2019 | 47 | Male | Moderately differentiated invasive adenocarcinoma | T2N0M0 | Pb | Unknown | DP  | 4 | 22G | 28 mo | CT/EGD | Posterior gastric wall | Unknown | PG | Died 17.4 mo after diagnosis |
| Yane *et al*[40] 2019 | 79 | Female | Poorly differentiated invasive adenocarcinoma | T1N0M0 | Pb | Unknown | DP  | 3 | 22G | 6 mo | CT/EGD | Posterior gastric wall | Unknown | PG | Alive 40.5 mo after diagnosis |
| Yane *et al*[40] 2019 | 78 | Female | Moderately differentiated invasive adenocarcinoma | T1N0M0 | Pb | Unknown | DP  | 4 | 22G | 35 mo | CT/EGD | Posterior gastric wall | Unknown | PG | Alive 4.6 mo after diagnosis |
| Yamaguchi *et al*[28] 2020 | 78 | Male | Solid pseudopapillary neoplasm | Unknown | Pb | 60 | Surgical resection  | 4 | 22G | 67 mo | Symptom/EGD/PET-CT | Posterior gastric wall | 40 | DG | Unknown |
| Sato *et al*[19] 2020 | 83 | Female |  Invasive ductal carcinoma | T2N2M0 | Pb | 25 | DP and CHE | 2 | 22G | 25 mo | CA19-9/MDCT/EUS | Posterior gastric wall | 25 | PG and lymph node resection |  No recurrence after 5 mo of follow-up |
| Rothermel *et al*[20] 2020 | 61 | Male | Invasive well differentiated pancreatic ductal adenocarcinoma  | T3N0M0 | Pb | 37 | DP and CHE | 3 | 25G | 3.5 yr | CA19-9/PET-CT/EGD | Posterior gastric wall | 25 | PG and CHE | No recurrence after 6 yr of follow-up |
| Kawabata *et al*[34] 2019 | 78 | Female | Invasive moderately differentiated ductal adenocarcinoma | T1N0M0 | Pb | 10.8 | DP | Unknown | 22G | 3 yr | CT | Posterior gastric wall | 25 | PG | Unknown |

DP: Distal pancreatectomy; CHE: Chemotherapy; PG: Partial gastrectomy; EGD: Esophagogastroduodenocopy; Pb: Pancreatic body; Pt: Pancreatic tail; CT: Computed tomography; MDCT: Multidetector computed tomography; DG: Distal gastrectomy.

**Table 2 Characteristics of reported needle tract seeding of other tumors**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Age**  | **Sex** | **Pathological diagnosis**  | **Staging** | **Location**  | **Size, mm** | **Initial treatment** | **Frequency of puncture** | **Needle gauge** | **Time interval**  | **Details of needle tract seeding** |
| **Discovery** | **Location** | **Maximum diameter (mm)** | **Treatment** | **Outcome** |
| Shah *et al*[59] 2004 | 39 | Female | Metastatic melanoma | Unknown | Perigastric lymph node | 24 | Surgical resection, chemotherapy | Transgastric/1 | 22G | 6 mo | Operative finding | Posterior gastric wall | 30 | Surgery | Unkonwn |
| Doi *et al*[60]  2008 | 70 | Male | Metastatic adenocarcinoma | Unknown | Mediastinal lymph node | 30 | Chemotherapyand distal gastrectomy | Transesophageal/1 | 19G | 22 mo | EGDS/EUS-FNA | Esophageal wall  | 4 | Radiation |  Lesion resolved after 2 mo |
| Anderson *et al*[61] 2013 | 51 | Male | Adenocarcinoma | Unknown |  Celiac lymph node | 6 | Chemoradiation therapy | Transgastric/ unknown | Unknown | Unknown | Symptom/EGDS/EUS-FNA | Gastroesophageal junction | 10 | Unknown | Unknown |
| Yokoyama *et al*[62] 2017 | 53 | Male | Mediastinal embryonal adenocarcinoma | Unknown | Mediastinum | 60 |  Unknown | Transesophageal/3 | 22G | 1 mo | CT | Esophageal wall  | Unknown | Chemotherapy |  Died less than 2 yr after Chemotherapy |
| Goel *et al*[63] 2017 | 57 | Male | Squamous cell carcinoma | Unknown | Coeliac space | 52 | Unknown | Transgastric /2 | 19G | 11 mo | Symptom/EGDS | Posterior gastric wall | 50 | Unsuitable for proximal gastrectomy | Unkonwn |

EGDS: Elective esophago-gastro-duodenoscopy; EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration; CT: Computed tomography.